TG Therapeutics

Yahoo Finance • last month

BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)

TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 26, TG Therapeutics Inc. (NASDAQ:TGTX) reported Q4 revenue of $192.6 million compared with consensus estimates of... Full story

Yahoo Finance • last month

How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio

In early March 2026, Precision BioSciences announced it hit a clinical milestone under its license with TG Therapeutics for azercabtagene zapreleucel in progressive multiple sclerosis, triggering a US$7.5 million payment that combines US$5... Full story

Yahoo Finance • 2 months ago

Soleus Adds a Significant Number of Celcuity Shares

Key Points Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter. Celcuity now accounts for 6.7% of fund AUM10 stocks we like better than Celcuity › On Feb. 12, Soleus Capi... Full story

Yahoo Finance • 2 months ago

Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 15, Goldman Sachs raised its price target on TG Therapeutics, Inc. (NASDAQ:TGTX) to $39 from $37 while maintaining a Neutral rating. The firm e... Full story

Yahoo Finance • 2 months ago

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration with actress Christina Applegate to h... Full story

Yahoo Finance • 2 months ago

Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares

Key Points Hussman Stratgic Advisors sold 126,000 shares of TG Therapeutics. The fund no longer holds any shares. The stake previously represented 1% of fund AUM as of the prior quarterThese 10 stocks could mint the next wave of millionai... Full story

Yahoo Finance • 4 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference... Full story

Yahoo Finance • 5 months ago

TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the TD Cowen Immunology & Inflammation Summit... Full story

Yahoo Finance • 5 months ago

RSI Alert: TG Therapeutics (TGTX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 5 months ago

Roche posts late-stage trial wins for new multiple sclerosis therapy

[Roche Diagnostics campus facade in Silicon Valley] Michael Vi/iStock Editorial via Getty Images Roche (OTCQX:RHHBY [https://seekingalpha.com/symbol/RHHBY]) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple scl... Full story

Yahoo Finance • 5 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing sched... Full story

Yahoo Finance • 6 months ago

ClearBridge Value Strategy adds AMZN, TSM, CRM, exits INTC, ABBV, EXPE among Q3 moves

The ClearBridge Value Strategy underperformed in its Russell 1000 Value Index benchmark in the third quarter, despite positive contributions from six out of the 11 sectors in which it was invested. The ClearBridge Value Strategy, in its f... Full story

Yahoo Finance • 7 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of contin... Full story

Yahoo Finance • 7 months ago

TG Therapeutics Breaks Above 200-Day Moving Average - Bullish for TGTX

In trading on Monday, shares of TG Therapeutics Inc (Symbol: TGTX) crossed above their 200 day moving average of $34.34, changing hands as high as $35.07 per share. TG Therapeutics Inc shares are currently trading up about 8% on the day.... Full story

Yahoo Finance • 7 months ago

CXW Makes Bullish Cross Above Critical Moving Average

In trading on Thursday, shares of CoreCivic Inc (Symbol: CXW) crossed above their 200 day moving average of $20.91, changing hands as high as $21.45 per share. CoreCivic Inc shares are currently trading up about 4.5% on the day. The char... Full story

Yahoo Finance • 7 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosi... Full story

Yahoo Finance • 7 months ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company’s anti-CD20 monoclonal an... Full story

Yahoo Finance • 7 months ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Inves... Full story

Yahoo Finance • 7 months ago

TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback

TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an additional $100 million buyback authorization.... Full story

Yahoo Finance • 7 months ago

Stocks making the biggest moves midday: Alphabet, Bruker, Sprinklr, Dollar Tree & more

Check out the companies making the biggest moves midday: Bruker – The diagnostics solutions stock dropped more than 11% after it announce the sale of $600 million in convertible stocks. The decline puts Bruker on pace for its biggest one-d... Full story